Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.45 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | AGXT | P21549 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763899 | 0.83 | PREP (0.53) | PREPCA12CA1CA9 | |
| SCHEMBL12426281 | 0.82 | PREP (0.46) | PREPCA12CA1CA9 | |
| SCHEMBL1601708 | 0.82 | PREP (0.46) | PREPCA12CA1CA9DRD2 | |
| SCHEMBL4785220 | 0.82 | PREP (0.50) | PREPCA12CA1CA9 | |
| SCHEMBL2087006 | 0.81 | PREP (0.45) | PREPCA12CA1CA9DRD2 | |
| SCHEMBL318210 | 0.81 | PPARA (0.47) | PREPCA12CA1CA9DRD2 | |
| SCHEMBL4676713 | 0.81 | IDO1 (0.50) | PREPCA12CA1CA9DRD2 | |
| SCHEMBL14384880 | 0.81 | PREP (0.45) | PREPCA12CA1CA9DRD2 | |
| SCHEMBL11957424 | 0.81 | PREP (0.45) | PREPCA12CA1CA9 | |
| SCHEMBL31643222 | 0.81 | PREP (0.49) | PREPCA12CA1CA9IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723860-B2 | 7a-alkoxy-4H-pyrano[3,2-d]-oxazol-2(3H)-one and process for producing the same | UBE INDUSTRIES, LTD. (JP) | 2004-04-20 | — | — | US | disclosed |
| EP-1207162-B1 | 7a-alkoxy-4H-pyrano-[3,2-d]-oxazol-2(3H)-one and process for producing the same | UBE INDUSTRIES (JP) | 2004-02-25 | — | — | EP | disclosed |
| US-20020072612-A1 | 7a-alkoxy-4H-pyrano [3,2-d] -oxazol-2 (3H) -one and process for producing the same | UBE INDUSTRIES, LTD. (JP) | 2002-06-13 | — | — | US | disclosed |
| EP-1207162-A1 | 7a-alkoxy-4H-pyrano-[3,2-d]-oxazol-2(3H)-one and process for producing the same | Ube Industries, Ltd. (JP) | 2002-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072612-A1 | 7a-alkoxy-4H-pyrano [3,2-d] -oxazol-2 (3H) -one and process for producing the same | ACSL1, ACSL4, ACSL3 | PREP 4570/4885CA12 3922/4885CA1 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.